Phase 3 randomized double-blind controlled trial of Cabozantinib (XL 184) vs Mitoxantrone plus Prednisone in men with previously treated symptomatic castration-resistant prostate cance (XL 184-306)
- Parente, Phillip (Primary Chief Investigator (PCI))
Project: Research